RedHill Biopharma Ltd.: Form 20-F for the period ended Dec 31, 2017
Filed with the SEC on Feb 22, 2018 and accepted by EDGAR at Feb 22, 2018, 07:17 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2017-01-01 to 2017-12-31 | $4.0m | ifrs-full:Revenue |
| Cost of revenue | 12 months2017-01-01 to 2017-12-31 | $2.1m | ifrs-full:CostOfSales |
| Gross profit | 12 months2017-01-01 to 2017-12-31 | $1.9m | ifrs-full:GrossProfit |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$52.0m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months2017-01-01 to 2017-12-31 | −$45.5m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | −$0.26 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | −$0.26 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | −$44.8m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $146.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2017-12-31 | $16.5m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2017-12-31 | $51.7m | ifrs-full:CurrentAssets |
| Total assets | At period end2017-12-31 | $57.3m | ifrs-full:Assets |
| Current liabilities | At period end2017-12-31 | $11.8m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2017-12-31 | $12.3m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $45.1m | ifrs-full:Equity |
| Shares outstanding | At period end2017-12-31 | 212,729,434 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001558370-18-000892. Last ingested by Listed: Nov 2, 2026, 07:05 ET. Listed shows no prices and gives no investment advice.